National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 6) (PB 60 of 2017) (Cth)
PB 60 of 2017
National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 6)
National Health Act 1953
I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated 27 July 2017
LOUISE CLARKE
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
Part 1 Preliminary
Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 6).
(2) This Determination may also be cited as PB 60 of 2017.
Commencement
This Determination commences on 1 August 2017.
Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1 Amendments
(Section 3)
[1] Schedule 1, after item dealing with Bortezomib
Omit
Bosentan
[2] Schedule 1, after item dealing with Choriogonadotropin alfa
Omit
Chorionic gonadotrophin
[3] Schedule 1, after item dealing with Nivolumab
Omit
Nortriptyline
[4] Schedule 1, after item dealing with Praziquantel
Omit
Pregabalin
[5] Schedule 1, after item dealing with Tenecteplase
Omit
Tenofovir
[6] Schedule 1, after item dealing with Ustekinumab
Omit
Valganciclovir
[7] Schedule 2, after item dealing with Bleomycin
Insert
Bosentan
[8] Schedule 2, after item dealing with Cephazolin
Insert
Chorionic gonadotrophin
[9] Schedule 2, after item dealing with Norfloxacin
Insert
Nortriptyline
[10] Schedule 2, after item dealing with Prednisone
Insert
Pregabalin
[11] Schedule 2, after item dealing with Temozolomide
Insert
Tenofovir
Tenofovir with emtricitabine
[12] Schedule 2, after item dealing with Valaciclovir
Insert
Valganciclovir
0
0
0